Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Close up of the Federal Reserve building with the eagle statue.

Deals

After Fed Rate Cut, Biotech Stocks Face ‘Anticlimactic’ Reality

The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change in the near term.

September 19, 2024

3 min read

Annalee Armstrong

FDA signage at its headquarters in Maryland

Complete response letters

Vanda Contests FDA Rejection of Gastroparesis Drug, Slams ‘Delayed’ Decision

Vanda Pharmaceuticals on Thursday announced that the regulator declined to approve its application, a decision the company says was delayed by more than 185 days and failed to satisfy the requirements of the Federal Drug and Cosmetic Act.

September 19, 2024

2 min read

Tristan Manalac

Facade of AstraZeneca's office in Shanghai, China

Approvals

AstraZeneca Wins Rare Autoimmune Indication for Asthma Biologic Fasenra

With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.

September 19, 2024

2 min read

Tristan Manalac

GSK's headquarters office building in Poznan, Poland

Vaccines

GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.

September 19, 2024

2 min read

Tristan Manalac

Gene therapy

4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies

4D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for annualized standard-of-care injections in patients with wet age-related macular degeneration.

September 19, 2024

2 min read

Tristan Manalac

Employees wonder how to evaluate job security

Career Advice

Evaluating Job Security in a Tough Biopharma Market

Job security is a hot topic among biopharma professionals. A career coach offers advice for how to evaluate and build it up and what to do if that evaluation leaves you worried.

September 19, 2024

5 min read

Angela Gabriel

Good company culture is beneficial for both employer and employee

Career Advice

11 Signs of Good Company Culture

Good company culture is a crucial aspect of professional life. Look at these 11 important indications of good workplace culture before accepting a job offer or use them to evaluate your new employer.

September 19, 2024

4 min read

Editorial Staff

PBMs

Deep Dive: PBM Reform

In the battle over drug prices, one sector of the healthcare industry has risen above all the players as the boogeyman: pharmacy benefit managers. In this special edition of BioPharm Executive, BioSpace takes a deep dive into the lens now focused on PBMs’ business practices.

September 18, 2024

2 min read

Annalee Armstrong